



Open Monoclonal Technology grants OmniAb license to The University of Nottingham

Palo Alto, CA, March 18, 2015

Open Monoclonal Technology, Inc. (OMT) has granted The University of Nottingham a license to OMT's proprietary OmniRat[®], OmniMouse[®] and OmniFlic[™] platforms for generation of human antibody therapeutics. The university will use the technology for novel cancer antigens.

Dr. Roland Buelow, founder and CEO of OMT, commented, "OMT's goal is to make its human antibody platforms available as broadly as possible. Professor Durrant has demonstrated academic leadership in development of therapeutic antibodies specific for tumor glycolipids. We hope access to OMT's technology and expertise will facilitate rapid progress with this novel approach."

Dr. Lindy Durrant, Professor at The University of Nottingham, continued, "This is a great opportunity for The University of Nottingham as it will put us at the forefront of monoclonal antibody development. The OmniRat, OmniMouse and OmniFlic platforms will allow us to make fully human antibodies that can be fast tracked into the clinic for the benefit of cancer patients."

About Open Monoclonal Technology, Inc.

Open Monoclonal Technology, Inc. (OMT) is a leader in genetic engineering of animals for generation of human therapeutic antibodies, *naturally optimized human antibodies*[®], and the only company in the world with four transgenic animal platforms, jointly *OmniAb*[™].

OmniRat[®] is the industry's first human monoclonal antibody technology based on rats. It has a complete immune system with a diverse antibody repertoire and generates antibodies with human idiotypes as well as wild-type animals make rat antibodies. *OmniMouse*[®] is a transgenic mouse that complements OmniRat and expands epitope coverage. *OmniFlic*[™] is an engineered rat with a fixed light chain for development of bispecific, fully human antibodies. *UniRat*[™] is the first transgenic rat generating fully human heavy chain-only antibodies and nanobodies for polyspecific applications.

All four OmniAb[™] platforms deliver human antibodies with high affinity, specificity, expression, solubility and stability. They use patented technology, have broad freedom to operate and are available worldwide for all targets and indications. Current partners include Celgene, Chugai, Genmab, Genentech, HanAll, Janssen, Merck KGaA, Pfizer, Roche, Symphogen, an undisclosed global pharmaceutical company and several smaller biotech companies and universities. OmniAb antibody discovery services are available via Antibody Solutions in the US, Aldevron in Germany and WuXi AppTec in China.

For more information, please visit www.omtinc.net or contact Chief Business Officer Brian Lundstrom, Phone: +1-775-420-7750, E-mail: bl@omtinc.net.